Biocon secures EMA approval for Semglee production line
pre-market1 source ↓written by the desknot a recommendation
- to ₹437.2
- 0.6%
- Mylan executed
- ₹3,680 cr block deal
Biocon received EMA approval for its Semglee insulin production line at its Malaysian plant, facilitating supply to Europe with shipments anticipated in FY27. Following the news, Biocon's shares rose 0.6% to ₹437.2. Additionally, Mylan executed a ₹3,680 cr block deal, selling 9.2 crore shares to Indian mutual funds.
Not investment advice. For informational purposes only.